Event Recap: From Strategy to Startup, Building the Company Behind Your Medtech Innovation
November 6, 2026
You have identified an unmet clinical need and developed a strategy for addressing it. What comes next? Turning that strategy into a company requires decisions about who will help, how the business will operate, what the product must demonstrate, and how the work will be funded.
On November 5, 2026, Chrysalis Incubator brought together Darryl Barnes, Mark Gardner, Brendon Pittman, Benjamin Tramm, Ted Dale, and Jeff Steinle for From Strategy to Startup: Building the Team, Company, & Capital Behind a Medtech Innovation.
Moderated by Pittman, the discussion explored Phase One of the Chrysalis process: creating the structure and assembling the people needed to execute the strategies developed during Phase Zero. The panel drew on experience building medical technologies and advising companies from formation through commercialization and exit.
Watch the Full Webinar Below
Download the Slides
Keep the Clinical Need at the Center
Darryl Barnes opened by revisiting the foundation of the Chrysalis process: clearly defining an unmet need, evaluating potential solutions, and developing the strategies needed to bring the strongest concept forward.
Drawing on his experience co-founding Sonex Health, Barnes explained how understanding patients’ concerns about surgery, recovery, and cost helped shape the company’s approach to ultrasound-guided surgery. Those considerations influenced product design, the intended treatment setting, and the value the technology needed to provide.
That focus continues as development begins. Barnes emphasized involving clinicians beyond the founding team to understand how a product would fit into their practices. Early feedback can reveal usability concerns or adoption barriers while the team still has room to adjust.
Build the Company and Product Together
Jeff Steinle described company formation as creating the structure that will hold the venture’s assets, receive investment, and support its growth. Founder agreements, ownership arrangements, and governance deserve attention early, alongside the technical work.
Benjamin Tramm explained why collaboration also requires clarity about intellectual property. Engineers, consultants, and other contributors may develop valuable improvements as they solve problems. Appropriate agreements help establish ownership, while confidentiality protections support the exchange of sensitive information.
Ted Dale highlighted the value of making ideas tangible through CAD models and early prototypes. A physical model can help clinicians, engineers, patent counsel, and prospective partners understand the concept and identify questions that a drawing or verbal explanation may leave unresolved.
As the product changes, the surrounding strategy needs to keep pace. Tramm emphasized aligning patent protection with both the evolving design and the parts of the business that create value. Mark Gardner connected regulatory planning to the same process, explaining how the anticipated FDA pathway influences development work, timing, and financing needs.
Match the Team and Capital to the Plan
Barnes encouraged founders to bring in complementary expertise and operational support, especially when they are building a company alongside a full-time job. Someone needs to coordinate meetings, track assignments, manage timelines, and keep decisions moving.
The panel discussed several ways to assemble that support, including co-founders, employees, consultants, and advisors. Steinle explained how carefully structured equity incentives can help attract and retain contributors when available cash is limited.
Capital planning also needs to begin early. Steinle recommended working backward from the intended outcome and identifying the milestones that could increase the company’s value, the funding required to reach them, and the investors suited to each stage.
Keeping those efforts connected takes ongoing attention. Barnes emphasized regular meetings, shared goals, and milestone reviews so that changes in engineering, intellectual property, regulatory strategy, clinical evidence, or reimbursement are understood across the team.
Take the Next Step With Chrysalis
Moving from strategy to startup means putting a practical plan into motion with people who understand how their work affects the rest of the business. The webinar showed how early coordination can help founders recognize gaps, make informed decisions, and reduce avoidable rework.
Chrysalis Incubator helps inventors, clinicians, and entrepreneurs evaluate medical technology opportunities and develop the strategies, relationships, and resources needed to move forward. Whether you are validating an unmet need, refining an early prototype, or assembling your team, our multidisciplinary perspective can help you identify your next steps.
Watch the recording above, explore our earlier Phase Zero recap, and contact info@ChrysalisIncubator.com to discuss your innovation.